Full 1
Consultancy Services in Drug
Discovery & Development.

Pharmacokinetics (PK), Pharmacodynamics ( PD) ,
Pharmacokinetics (PK) / Pharmacodynamics (PD)

Know more

Why PK, PD, PK/PD?

Pharmacokinetics

PK drives efficacy and safety of a molecule. Optimization of PK is essential to maximize pharmacological effect in animals and humans.

Pharmacodynamics

The quantification of onset, intensity and duration of pharmacological effect helps in characterizing the intrinsic pharmacodynamics (efficacy) of a molecule in animals and humans.

Pharmacokinetics / Pharmacodynamics

Quantitating the PK/PD of a molecule forms the basis for setting dose, dose frequency and duration of treatment in preclinical and clinical settings.

About us

DOSE QUANTICS

DoseQuantics Consulting provides consultancy services in drug discovery and development in areas of lead identification, lead optimization, preclinical development and clinical development.
About us_Tablet_2

Our Services

PHARMACOKINETICS (PK)

  • Estimation of Non-compartmental PK
    parameters in preclinical species and humans
  • Estimation of Compartmental PK parameters
    in preclinical species and humans
  • Dose Proportionality Analysis

PHARMACODYNAMICS (PD)

  • Estimation of in vitro Pharmacodynamic parameters
  • Estimation of in vivo Pharmacodynamic parameters
  • Modelling of Pharmacodynamic data in preclinical species

PHARMACODYNAMICS (PD)

  • Estimation of in vitro
    Pharmacodynamic parameters
  • Estimation of in vivo
    Pharmacodynamic parameters
  • Modelling of Pharmacodynamic
    data in preclinical species

PHARMACOKINETICS/ PHARMACODYNAMICS (PK/PD)

  • Design of PK/PD studies, analysis and
    Interpretation of PK/PD data
  • Dose Exposure Response analysis
  • Modelling and Simulation of PK/PD data

Testimonials

What our clients say about working with DoseQuantics Consulting.

“
★★★★★

"Ramesh Jayaraman of DoseQuantics Consulting has supported FNDR as a PK/PD advisor across our infectious diseases drug discovery programmes. His expertise in pharmacokinetics and translational PK/PD has helped strengthen our preclinical decision-making."

R
Dr. R K Shandil
Co-founder & Director
Foundation for Neglected Disease Research